FDA: Safety Alert on liquid-filled intragastric balloon systems
Editor's Note
The Food and Drug Administration (FDA) on August 10 issued a Safety Alert to update healthcare providers on five reports of unanticipated deaths that have occurred from 2016 to the present in patients with liquid-filled intragastric balloon systems used to treat obesity.
Four reports involve the Orbera Intragastric Balloon System, manufactured by Apollo Endo Surgery (San Diego, California), and one involves the ReShape Integrated Dual Balloon System, manufactured by ReShape Medical Inc (San Clemente, California).
At this time, the FDA says it does not know the root cause or incidence rate of patient deaths, nor have they been able to definitively attribute the deaths to the devices or insertion procedures.
All five deaths occurred within 1 month or less of balloon placement.
Posted 08/10/2017] AUDIENCE: Surgery, Gastroenterology, Health Professional ISSUE: FDA is issuing an update to alert health care providers of five reports of unanticipated deaths that occurred from 2016 to present in patients with liquid-filled intragastric balloon systems used to treat obesity.
Read More >>
Free Daily News
- FDA medical device class 1 recalls trend upward
- Data cast doubt on recommendation to delay weight-loss meds prior to surgery
- AAMI guidance covers sterile processing of dilators, ultrasound probes
- Surgical site infections often caused by preexisting bacteria
- The Joint Commission launches new telehealth accreditation program
- FDA announces class 1 recall for disposable biopsy needle kit
- Report: Consistent, purposeful manager-team engagement reduces RN turnover
- Death, hospital readmission less likely for women treated by female doctors
- FDA announces class 1 recalls for infusion pumps, anesthesia workstation
- Study finds workforce readiness gap in new nurses